“We are pleased with the incredible progress we have made since the beginning of the third quarter, including the U.S. launch of XACIATO and moving several of our product candidates forward, further positioning the company for long-term success,” said Sabrina Martucci Johnson, President and CEO of Dare Bioscience. “The fourth quarter is also proving to be a busy one for Dare, and we remain on track to have multiple meaningful milestones by the end of 2023 as we execute on our mission to accelerate development of and bring to market innovative treatments that women want and need.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DARE:
- Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update
- Dare Bioscience announces data from Phase 2b RESPOND study
- Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program
- Biotech Alert: Searches spiking for these stocks today
- Dare Bioscience announces first shipment of XACIATOTM